Achaogen Inc (AKAO) Stock Price, Forecast & Analysis

NASDAQ:AKAO

0.11
+0 (+2.23%)
At close: Apr 25, 2019
0.12
+0.01 (+9.09%)
After Hours: 4/25/2019, 9:59:14 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AKAO Key Statistics, Chart & Performance

Key Statistics
Market Cap7.03M
Revenue(TTM)8.73M
Net Income(TTM)-186.51M
Shares63.88M
Float54.19M
52 Week High15
52 Week Low0.1
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-3.7
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
AKAO short term performance overview.The bars show the price performance of AKAO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

AKAO long term performance overview.The bars show the price performance of AKAO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AKAO is 0.11 null. In the past month the price decreased by -76.66%. In the past year, price decreased by -99.16%.

Achaogen Inc / AKAO Daily stock chart

AKAO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
AKAO Full Technical Analysis Report

AKAO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AKAO. AKAO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AKAO Full Fundamental Analysis Report

AKAO Financial Highlights

Over the last trailing twelve months AKAO reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS decreased by -16.72% compared to the year before.


Industry RankSector Rank
PM (TTM) -2136.94%
ROA -226.65%
ROE 2966.63%
Debt/Equity -3.94
Chartmill High Growth Momentum
EPS Q2Q%30.61%
Sales Q2Q%8.35%
EPS 1Y (TTM)-16.72%
Revenue 1Y (TTM)-21.9%
AKAO financials

AKAO Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y65.68%
Revenue Next YearN/A
AKAO Analyst EstimatesAKAO Analyst Ratings

AKAO Ownership

Ownership
Inst Owners0.02%
Ins Owners27.76%
Short Float %N/A
Short RatioN/A
AKAO Ownership

About AKAO

Company Profile

Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.

Company Info

Achaogen Inc

1 TOWER PLACE SUITE 300

SOUTH SAN FRANCISCO CA 94080

CEO: Blake Wise

Phone: 650-800-3636

Achaogen Inc / AKAO FAQ

What does Achaogen Inc do?

Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.


What is the stock price of Achaogen Inc today?

The current stock price of AKAO is 0.11 null. The price increased by 2.23% in the last trading session.


What is the dividend status of Achaogen Inc?

AKAO does not pay a dividend.


What is the ChartMill rating of Achaogen Inc stock?

AKAO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the ownership details for AKAO stock?

You can find the ownership structure of Achaogen Inc (AKAO) on the Ownership tab.